<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Onward Medical N.v. — News on 6ix</title>
    <link>https://6ix.com/company/onward-medical-nv-1</link>
    <description>Latest news and press releases for Onward Medical N.v. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 05:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/onward-medical-nv-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d68f03beedb30cb6fefc5b.webp</url>
      <title>Onward Medical N.v.</title>
      <link>https://6ix.com/company/onward-medical-nv-1</link>
    </image>
    <item>
      <title>ONWARD Medical Successfully Raises over EUR 40 Million in Capital Increase</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-successfully-raises-over-eur-40-million-in-capital-increase</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-successfully-raises-over-eur-40-million-in-capital-increase</guid>
      <pubDate>Thu, 16 Apr 2026 05:30:00 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Transaction includes EUR 25.0M investment from EQT Life SciencesStron</description>
    </item>
    <item>
      <title>ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 40 Million</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-launches-capital-increase-for-indicative-amount-of-eur-40-million</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-launches-capital-increase-for-indicative-amount-of-eur-40-million</guid>
      <pubDate>Wed, 15 Apr 2026 16:19:00 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Private placement includes participation of EQT Life Sciences, which</description>
    </item>
    <item>
      <title>ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-publishes-convocation-of-the-2026-annual-general-meeting-of-shareholders-and-proposed-resolutions-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-publishes-convocation-of-the-2026-annual-general-meeting-of-shareholders-and-proposed-resolutions-1</guid>
      <pubDate>Wed, 01 Apr 2026 06:45:00 GMT</pubDate>
      <description>EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today convened the 2026 Annual General Meeting of Shareholders (AGM), which will be held in Amsterdam, the Netherlands, on May 13, 2026. The resolutions proposed by the Board, to be submitted for adoptio</description>
    </item>
    <item>
      <title>ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-reports-full-year-2025-financial-and-operating-results-highlighting-strong-us-commercial-performance-and-major-pipeline-milestones</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-reports-full-year-2025-financial-and-operating-results-highlighting-strong-us-commercial-performance-and-major-pipeline-milestones</guid>
      <pubDate>Tue, 31 Mar 2026 05:30:00 GMT</pubDate>
      <description>THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its financial and operating results for the full year</description>
    </item>
    <item>
      <title>ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-schedules-webcast-to-report-full-year-2025-financial-results-and-provide-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-schedules-webcast-to-report-full-year-2025-financial-results-and-provide-business-update</guid>
      <pubDate>Mon, 23 Mar 2026 06:30:00 GMT</pubDate>
      <description>EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that it will report Full-Year 2025 Financial Results and host a webcast to provide a comprehensive business update on March 31, 2026. Presented by CEO Dave Marver, the webcast will be held at 2:0</description>
    </item>
    <item>
      <title>ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-announces-first-participant-enrolled-in-global-pivotal-study-evaluating-arc-im-system-to-address-blood-pressure-instability-after-spinal-cord-injury-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-announces-first-participant-enrolled-in-global-pivotal-study-evaluating-arc-im-system-to-address-blood-pressure-instability-after-spinal-cord-injury-1</guid>
      <pubDate>Wed, 04 Feb 2026 06:30:00 GMT</pubDate>
      <description>Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood pressure instability is a key unmet need after SCI, with a significant impact on cardiovascular health and quality of lifeThe first participant was enrolled at Craig Hospital in Denver, Colorado, USA EINDHOVEN, the Netherlands, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US O</description>
    </item>
    <item>
      <title>ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-appoints-ali-kiboro-as-chief-financial-officer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-appoints-ali-kiboro-as-chief-financial-officer-1</guid>
      <pubDate>Fri, 23 Jan 2026 06:30:00 GMT</pubDate>
      <description>EINDHOVEN, the Netherlands, Jan. 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, today announces the appointment of Ali Kiboro as Chief Financial Officer, effective January 2026. Ali brings more than 25 years of financial leadership experience across medical technology, tools and diagnostics, and general industry. He joins ONWARD Medical fro</description>
    </item>
    <item>
      <title>ONWARD Medical Completes Two Additional Brain-Computer Interface Implants Paired with Spinal Cord Stimulation Technology to Restore Thought-Driven Movement</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-completes-two-additional-brain-computer-interface-implants-paired-with-spinal-cord-stimulation-technology-to-restore-thought-driven-movement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-completes-two-additional-brain-computer-interface-implants-paired-with-spinal-cord-stimulation-technology-to-restore-thought-driven-movement-1</guid>
      <pubDate>Thu, 22 Jan 2026 06:30:00 GMT</pubDate>
      <description>Investigational ARC-BCI® Therapy is being developed to restore thought-driven movement in people living with spinal cord injuries and other movement disabilitiesARC-BCI is the world’s first and most advanced purpose-designed platform pairing a brain-computer interface with an implantable spinal cord stimulation system Seven study participants have now received ARC-BCI Therapy to restore movement of their own paralyzed limbs EINDHOVEN, the Netherlands, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ONWARD Med</description>
    </item>
    <item>
      <title>ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-drives-strong-us-arc-ex-adoption-and-achieves-important-scientific-and-regulatory-milestones-in-q3-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-drives-strong-us-arc-ex-adoption-and-achieves-important-scientific-and-regulatory-milestones-in-q3-2025-1</guid>
      <pubDate>Mon, 24 Nov 2025 06:30:00 GMT</pubDate>
      <description>EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced its results for the third quarter of 2025 and provides a comprehensive business update: Commercial traction: The Company met its objective of 40 ARC-EX® Systems sold in Q3.Regulatory miles</description>
    </item>
    <item>
      <title>ONWARD Medical Receives FDA 510(k) Clearance Expanding ARC-EX System Indication for Home Use</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-receives-fda-510k-clearance-expanding-arc-ex-system-indication-for-home-use-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-receives-fda-510k-clearance-expanding-arc-ex-system-indication-for-home-use-1</guid>
      <pubDate>Mon, 17 Nov 2025 06:30:00 GMT</pubDate>
      <description>THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) US FDA clearance now allows use of the ARC-EX® System both in clinics and homesARC-EX is the first and only FDA-cleared technology demonstrated to improve hand strength and sensation in people with spinal cord injuryYear to date, ARC-EX Systems have been purchased by more than 60 US clinics EINDHOVEN, the Netherlands, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ONWARD Medica</description>
    </item>
    <item>
      <title>ONWARD Medical Publishes Closing of Bookbuild Offering</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-publishes-closing-of-bookbuild-offering-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-publishes-closing-of-bookbuild-offering-1</guid>
      <pubDate>Tue, 28 Oct 2025 16:45:00 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONWARD</description>
    </item>
    <item>
      <title>ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-successfully-raises-over-eur-50-million-in-capital-increase-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-successfully-raises-over-eur-50-million-in-capital-increase-1</guid>
      <pubDate>Fri, 24 Oct 2025 05:30:00 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Successful transaction supported by strong demand from existing and n</description>
    </item>
    <item>
      <title>ONWARD Medical Launches Capital Increase for Indicative Amount of EUR 50 Million</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-launches-capital-increase-for-indicative-amount-of-eur-50-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-launches-capital-increase-for-indicative-amount-of-eur-50-million-1</guid>
      <pubDate>Wed, 22 Oct 2025 15:49:00 GMT</pubDate>
      <description>NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Private placement is expected to be anchored by multiple long-only in</description>
    </item>
    <item>
      <title>ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-provides-preliminary-q3-2025-update-highlighting-accelerating-arc-ex-adoption-in-the-united-states-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-provides-preliminary-q3-2025-update-highlighting-accelerating-arc-ex-adoption-in-the-united-states-1</guid>
      <pubDate>Mon, 13 Oct 2025 05:30:00 GMT</pubDate>
      <description>EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces the following key achievements in the third quarter of 2025: Commercial traction: 40 ARC-EX® Systems were sold in Q3, demonstrating continued strong commercial traction for the Company’s g</description>
    </item>
    <item>
      <title>Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/concurrent-publications-in-nature-and-nature-medicine-highlight-advances-in-blood-pressure-regulation-after-spinal-cord-injury-using-onward-arc-im-therapy-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/concurrent-publications-in-nature-and-nature-medicine-highlight-advances-in-blood-pressure-regulation-after-spinal-cord-injury-using-onward-arc-im-therapy-1</guid>
      <pubDate>Thu, 18 Sep 2025 05:30:00 GMT</pubDate>
      <description>Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most people living with spinal cord injury experience blood pressure instability, which represents a key unmet needToday’s concurrent publications provide clinical evidence for ARC-IM® Therapy ahead of the Company’s planned initiation of the Empower BP global pivotal trial later this year EINDHOVEN, The Neth</description>
    </item>
    <item>
      <title>ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-receives-ce-mark-for-arc-ex-enabling-commercial-launch-of-breakthrough-spinal-cord-stimulation-system-in-europe-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-receives-ce-mark-for-arc-ex-enabling-commercial-launch-of-breakthrough-spinal-cord-stimulation-system-in-europe-1</guid>
      <pubDate>Mon, 08 Sep 2025 06:44:00 GMT</pubDate>
      <description>THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The CE Mark certification allows marketing for both clinic and home useFirst commercial sales of the ARC-EX® System in Europe are expected in Q4 2025The CE Mark enables commercialization in the European Union and facilitates a streamlined regulatory pathway in other countries, including in the UK and Switzerland EINDHOVEN, the Netherlands, Sept. 08, 2025 (GLOBE NEW</description>
    </item>
    <item>
      <title>ONWARD Medical Demonstrates Commercial Traction and Advances Pipeline in the First Half of 2025</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-demonstrates-commercial-traction-and-advances-pipeline-in-the-first-half-of-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-demonstrates-commercial-traction-and-advances-pipeline-in-the-first-half-of-2025-1</guid>
      <pubDate>Tue, 02 Sep 2025 05:30:00 GMT</pubDate>
      <description>THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, The Netherlands, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its results for the first half of 2025: Commercial tra</description>
    </item>
    <item>
      <title>ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-receives-fda-ide-approval-to-initiate-the-empower-bp-pivotal-study-with-the-arc-im-system-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-receives-fda-ide-approval-to-initiate-the-empower-bp-pivotal-study-with-the-arc-im-system-1</guid>
      <pubDate>Mon, 18 Aug 2025 16:30:00 GMT</pubDate>
      <description>THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI).Managing blood pressure instability is a major unmet need after SCI, with a significant impac</description>
    </item>
    <item>
      <title>ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-announces-the-appointment-of-lucas-buchanan-to-its-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-announces-the-appointment-of-lucas-buchanan-to-its-board-of-directors-1</guid>
      <pubDate>Wed, 06 Aug 2025 05:30:00 GMT</pubDate>
      <description>Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the Vertical Group, is also an active investor, advisor, and board member for several innovative medical device companies and healthcare investment funds. EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading</description>
    </item>
    <item>
      <title>ONWARD Medical Adds Entrepreneur and Neurotechnology Thought Leader Tim Denison, PhD to its Board of Directors</title>
      <link>https://6ix.com/company/onward-medical-nv-1/news/onward-medical-adds-entrepreneur-and-neurotechnology-thought-leader-tim-denison-phd-to-its-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/onward-medical-nv-1/news/onward-medical-adds-entrepreneur-and-neurotechnology-thought-leader-tim-denison-phd-to-its-board-of-directors-1</guid>
      <pubDate>Mon, 07 Jul 2025 05:30:00 GMT</pubDate>
      <description>THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Denison is Professor of Clinical Neurosciences at the University of Oxford and was previously Vice President of Research and Core Technologies at Medtronic. He is a co-founder and Chief Engineer of neurotechnology company Amber Therapeutics.ONWARD Co-Founder Professor Gregoire Courtine will continue to serve as Science Advisor. He will depart the Board of Directors</description>
    </item>
  </channel>
</rss>